

Please type a plus sign (+) inside this box → [ ]



#18

PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p> <p>SHEET 1 of 1</p>	<b>COMPLETE IF KNOWN</b>	
	Application Number	09/694,519
	Confirmation Number	9641
	Filing Date	10/23/2000
	First Named Inventor	Robert J. Isfort
	Group Art Unit	1637
	Examiner Name	Teresa E. Strzelecka
Attorney Docket Number	8311	

### U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
TS	✓1	US-6,114,127	09/05/2000	Bergsma et al.	
		US-			

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
TS	✓2	WO 95/06724	03/09/1995	Medical Research Council		

### NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
TS	✓3	GOURLET, P. et al., "The Long-Acting Vasoactive Intestinal Polypeptide Agonist RO 25-1553 Is Highly Selective of the VIP <sub>2</sub> Receptor Subclass", <u>Peptides</u> , 1996, Vol. 18, pp. 403-408.	
	✓4	WEI, Y. et al., "Tissue Specific Expression of Different Human Receptor Types for Pituitary Adenylate Cyclase Activating Polypeptide and Vasoactive Intestinal Polypeptide: Implications for their Role in Human Physiology", <u>J. of Neuroendocrinology</u> , 1996, Vol. 8, pp. 811-817.	
	✓5	ADAMOU, J.E. et al., "Cloning and functional Characterization of the Human Vasoactive Intestinal Peptide (VIP)-2 Receptor", <u>Biochemical and Biophysical Research Communications</u> , 1995, Vol. 209, No. 2, pp. 385-392.	
	✓6	GOURLET, P. et al., "Development of High Affinity Selective VIP <sub>1</sub> Receptor Agonists", <u>Peptides</u> , 1997, Vol. 18, No. 10, pp. 1539-1545.	
TS	✓7	IGUCHI, G. et al., "Cloning and characterization of the 5'-Flanking Region of the Human Growth Hormone-releasing Hormone Receptor Gene", <u>J. of Biological Chem.</u> , 1999, Vol. 274, No. 17, pp. 12108-12114.	

EXAMINER <i>Teresa Strzelecka</i>	DATE CONSIDERED <i>12/16/03</i>
-----------------------------------	---------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

TECH CENTER 1600/2500  
SEP 02 2003  
RECL...